Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MET Positive”

57 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 57 results

Testing effectiveness (Phase 2)Study completedNCT03088930
What this trial is testing

Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer, Nonsmall Cell
University of Colorado, Denver 3
Testing effectiveness (Phase 2)Active Not RecruitingNCT03944772
What this trial is testing

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 247
Testing effectiveness (Phase 2)Active Not RecruitingNCT03778229
What this trial is testing

Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib

Who this might be right for
Carcinoma
AstraZeneca 367
Testing effectiveness (Phase 2)UnknownNCT05163249
What this trial is testing

Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Guangdong Association of Clinical Trials 44
Early research (Phase 1)Study completedNCT02978261
What this trial is testing

Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas

Who this might be right for
Glioma
Beijing Pearl Biotechnology Limited Liability Company 18
Not applicableEnrolling By InvitationNCT07122882
What this trial is testing

Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance

Who this might be right for
Oncogene-addicted Non Small Cell Lung CancerEGFR MutationALK Fusion-positive Solid or CNS Tumors+10 more
Chang Gung Memorial Hospital 40
Testing effectiveness (Phase 2)Looking for participantsNCT03175224
What this trial is testing

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Who this might be right for
Solid TumorsAdvanced CancerRenal Cancer+15 more
Apollomics Inc. 497
Not applicableNot Yet RecruitingNCT06797570
What this trial is testing

The Primary Objective of This Study is to Determine Whether Positively Framed Information (PFI) on Side Effects, Compared to Negatively Framed and Extensive Information (NFI) Can Reduce the Number and Severity of Reported Adverse Events Caused by ADHD Medication in Children Aged 7 to 17 Years.

Who this might be right for
Attention Deficit DisorderAttention Deficit Disorder (ADD)Attention Deficit Disorder with Hyperactivity+13 more
St. Antonius Hospital
Large-scale testing (Phase 3)Ended earlyNCT02137343
What this trial is testing

Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer

Who this might be right for
Gastric Cancer
Amgen 34
Testing effectiveness (Phase 2)Study completedNCT01874938
What this trial is testing

LY2875358 in Participants With MET Positive, Advanced Gastric Cancer

Who this might be right for
Gastric Cancer
Eli Lilly and Company 15
Large-scale testing (Phase 3)Study completedNCT02031744
What this trial is testing

The Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 530
Testing effectiveness (Phase 2)Looking for participantsNCT06116682
What this trial is testing

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Who this might be right for
Lung Non-Small Cell Carcinoma
SWOG Cancer Research Network 88
Early research (Phase 1)Not Yet RecruitingNCT07553793
What this trial is testing

Chimeric Antigen Receptor Macrophages Targeting c-MET for Advanced Stage of Pancreatic Cancer Patients

Who this might be right for
Pancreatic CancerAdvanced Stage Cancer
Peking Union Medical College Hospital 18
Post-approval studies (Phase 4)Study completedNCT05110196
What this trial is testing

Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.

Who this might be right for
Non-Small Cell Lung Carcinoma
Novartis Pharmaceuticals 50
Testing effectiveness (Phase 2)Study completedNCT01900652
What this trial is testing

Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Eli Lilly and Company 111
Testing effectiveness (Phase 2)Ended earlyNCT02612194
What this trial is testing

LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer

Who this might be right for
Urinary Bladder NeoplasmsUreteral NeoplasmsUrethral Neoplasms
Wake Forest University Health Sciences 8
Large-scale testing (Phase 3)Ended earlyNCT02926638
What this trial is testing

Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

Who this might be right for
MET PositiveRecurrent Squamous Cell Lung CarcinomaStage IV Squamous Cell Lung Carcinoma AJCC v7
SWOG Cancer Research Network 9
Not applicableStudy completedNCT04575025
What this trial is testing

Special Drug Use-results Surveillance of Tabrecta Tablets

Who this might be right for
Non-small Cell Lung Cancer
Novartis Pharmaceuticals 109
Testing effectiveness (Phase 2)Looking for participantsNCT07322783
What this trial is testing

Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification

Who this might be right for
EGFR Positive Non-small Cell Lung CancerMET Amplification
Qingdao Central Hospital 60
Large-scale testing (Phase 3)Study completedNCT01662869
What this trial is testing

Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer

Who this might be right for
Gastric Cancer
Hoffmann-La Roche 564
Next Page
130